Through PREP, we seek to continue to assess the use of PSMA PET in other indications, for example, in primary staging of medium or high-risk prostate cancer or in primary detection of tumor in complex cases where there exists clinical suspicion for prostate cancer despite a negative conventional workup, including multiparametric prostate MRI and systematic biopsies. This evidence concerns the gene FOLH1 and neoplasm.